Runx2 in human breast carcinoma: Its potential roles in cancer progression

Cancer Science

Volumn 101, Issue 12, 2010, Pages 2670-2675

  Onodera, Yoshiaki ^a,b   Miki, Yasuhiro ^a   Suzuki, Takashi ^a   Takagi, Kiyoshi ^a   Akahira, Jun Ichi ^a   Sakyu, Takuya ^a   Watanabe, Mika ^b   Inoue, Satoshi ^c   Ishida, Takanori ^a   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST CELL; BREAST DUCT; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78449307996     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01742.x     Document Type: Article

References (51)

1. Gnant M, Dubsky P, Fitzal F et al. Austrian Breast and Colorectal Cancer Study Group. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin Breast Cancer 2009; 9(Suppl 1): S18-27.
2. Guise TA, Yin JJ, Taylor SD et al. Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-9.
3. Burtis WJ, Brady TG, Orloff JJ et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322: 1106-12.
4. Southby J, Kissin MW, Danks JA et al. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res 1990; 50: 7710-6.
5. Uy HL, Mundy GR, Boyce BF et al. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997; 57: 3194-9.
6. Liu BY, Guo J, Lanske B, Divieti P, Kronenberg HM, Bringhurst FR. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 1998; 139: 1952-64.
7. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-71.
8. Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s-6s.
9. Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009; 16: 703-13.
10. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609-17.
11. Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther 2008; 7: 3-9.
12. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-87.
13. Osato M, Asou N, Abdalla E et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817-24.
14. Song W-J, Sullivan MG, Legare RD et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-75.
15. Ito K, Lim AC, Salto-Tellez M et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 2008; 14: 226-37.
16. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-54.
17. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-64.
18. Otto F, Thornell AP, Crompton T et al. Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development. Cell 1997; 89: 765-71.
19. Mundlos S, Otto F, Mundlos C et al. Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia. Cell 1997; 89: 773-9.
20. San Martin IA, Varela N, Gaete M et al. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. J Cell Physiol 2009; 221: 560-71.
21. Pereira BP, Zhou Y, Gupta A et al. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol 2009; 221: 778-88.
22. Inman CK, Sgore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278: 48684-9.
23. Javed A, Barnes GL, Pratap J et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005; 102: 1454-9.
24. Pratap J, Javed A, Languino LR et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005; 25: 8581-91.
25. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56: 13-22.
26. Pratap J, Galindo M, Zaidi SK et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003; 63: 5357-62.
27. Galindo M, Pratap J, Young DW et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 2005; 280: 20274-85.
28. Inman CK, Li N, Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 2005; 25: 3182-93.
29. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005; 96: 484-9.
30. Pratap J, Wixted JJ, Gaur T et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008; 68: 7795-802.
31. Zelzer E, Glotzer DJ, Hartmann C et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001; 106: 97-106.
32. Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 2004; 279: 27764-73.
33. Barnes GL, Javed A, Waller SM et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63: 2631-7.
34. Das K, Leong DT, Gupta A et al. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 2009; 45: 2239-48.
35. Brown SA, Guise TA. Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 2009; 19: 47-60.
36. Miki Y, Suzuki T, Sasano H. Aromatase inhibitor and bone. Biomed Pharmacother 2007; 61: 540-2.
37. Fogelman I, Blake GM, Blamey R et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14: 1001-6.
38. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-92.
39. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
40. Mak IW, Cowan RW, Popovic S, Colterjohn N, Singh G, Ghert M. Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of bone. Bone 2009; 45: 377-86.
41. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005; 10: 1569-83.
42. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-75.
43. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
44. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
45. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
46. Itoh T, Tanioka M, Matsuda H et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 177-81.
47. Nakamura T, Imai Y, Matsumoto T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-23.
48. Cenci S, Weitzmann MN, Roggia C et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-37.
49. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106: 1203-4.
50. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005; 208: 207-27.
51. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81.